Publications by authors named "Jonathan Nazari"

Claim this Profile
P
Patient-Reported Outcome Measures in Clinical Trials: An Analysis of Trends from 2008-2023.
Maja Kuharic, Justin Yu, Mrinmayee Joshi, Jonathan Nazari, Fatih Zecic

Value Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valuing Child Health: An EQ-5D-Y-3L Value Set for the United States.
A Simon Pickard, Jonathan L Nazari, Juan M Ramos-Goñi, Ning Yan Gu

Value Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.
Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari

Prostate Cancer Prostatic Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and severity response scales for pain and discomfort: psychometric insights from EQ-HWB.
Soumana C Nasser, A Simon Pickard, Jonathan L Nazari, Maja Kuharic

Qual Life Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer.
Elena Castro, Rhett Figliuzzi, Sarah Walsh, Samantha Craigie, Jonathan Nazari

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Acquired Taste: Latent Class Analysis to Compare Adolescent and Adult Preferences for EQ-5D-Y-3L Health States.
Jonathan L Nazari, Juan M Ramos-Goñi, Ning Yan Gu, A Simon Pickard

Value Health· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.
Elena Castro, Di Wang, Sarah Walsh, Samantha Craigie, Anja Haltner, Jonathan Nazari

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.
Elena Castro, Jenna Ellis, Samantha Craigie, Anja Haltner, Jonathan Nazari

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer.
Imtiaz A Samjoo, Tim Disher, Elena Castro, Jenna Ellis, Stefanie Paganelli, Jonathan Nazari

Clin Genitourin Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perceptions of prescription opioids among marginalized patients with hematologic malignancies in the context of the opioid epidemic: a qualitative study.
Nadia A Nabulsi, Jonathan L Nazari, Todd A Lee, Pritesh R Patel, Karen I Sweiss

J Cancer Surviv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease.
Maja Kuharic, Victoria Kulbokas, Kent Hanson, Jonathan L Nazari, Kanya K Shah

Parkinsonism Relat Disord· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of virtual academic detailing in North America: A qualitative study.
Jonathan L Nazari, Victoria Kulbokas, Mary H Smart, Tara R Hensle, Todd A Lee

J Eval Clin Pract· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of race on survival in metastatic prostate cancer: a systematic literature review.
Stephen J Freedland, Imtiaz A Samjoo, Emily Rosta, Austin Lansing, Evelyn Worthington, Jonathan Nazari

Prostate Cancer Prostatic Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access.
Michelle T Martin, Nicole Waring, Jasmine Forrest, Jonathan L Nazari, Abdullah I Abdelaziz

Public Health Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L.
Jonathan L Nazari, A Simon Pickard, Ning Yan Gu

Pharmacoeconomics· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drugs to Be Used With a Filter for Preparation and/or Administration-2019.
Heather J Ipema, Jessica M Zacher, Eva Galka, Jonathan Nazari, Alina Varabyeva

Hosp Pharm· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model.
Ying He, Diana J Wilkie, Jonathan Nazari, Rui Wang, Robert O Messing

J Clin Invest· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis